clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Fistula D005402 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Lymphadenitis D008199 8 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Klebsiella Infections D007710 7 associated lipids
Metaplasia D008679 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Tooth Discoloration D014075 7 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Bacteriuria D001437 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bronchiectasis D001987 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chlamydia Infections D002690 7 associated lipids
Stomach Diseases D013272 7 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Whooping Cough D014917 6 associated lipids
Bronchitis D001991 6 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Skin Ulcer D012883 6 associated lipids
Syphilis D013587 6 associated lipids
Tuberculosis, Multidrug-Resistant D018088 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Pyelonephritis D011704 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Rickettsia Infections D012282 5 associated lipids
Splenic Diseases D013158 5 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Duodenitis D004382 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Cysts D003560 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Confusion D003221 4 associated lipids
Prurigo D011536 4 associated lipids
Lymphangitis D008205 4 associated lipids
Barrett Esophagus D001471 3 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Fractures, Open D005597 3 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Soepandi P et al. The pattern of micro-organisms and the efficacy of new macrolide in acute lower respiratory tract infections. 1998 Respirology pmid:9692520
Ruiz-González A et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. 2007 Respirology pmid:17207036
Ding FM et al. Low-dose clarithromycin therapy modulates CD4(+) T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection. 2012 Respirology pmid:22404374
Kobashi Y et al. Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease. 2006 Respirology pmid:17052313
Okimoto N et al. Clinical features of Q fever pneumonia. 2004 Respirology pmid:15182283
Kikuchi E et al. Pharmacokinetics of clarithromycin in bronchial epithelial lining fluid. 2008 Respirology pmid:18339019
Isozumi R et al. Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae. 2009 Respirology pmid:19732389
Liapakis IE et al. Penetration of clarithromycin in experimental pleural empyema model fluid. 2005 May-Jun Respiration pmid:15942299
Rovira E et al. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. 1999 Respiration pmid:10516537
Huchon G How to manage the low-risk patient with lower respiratory tract infection? 1999 Respiration pmid:10577170
Kobashi Y and Matsushima T The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan - including a follow-up study. 2007 Respiration pmid:16954651
Jouneau S et al. Clarithromycin stops lung function decline in airway-centered interstitial fibrosis. 2013 Respiration pmid:23095475
Fujiuchi S et al. Analysis of chest CT in patients with Mycobacterium avium complex pulmonary disease. 2003 Jan-Feb Respiration pmid:12584395
Persson CG and Uller L Resolution of cell-mediated airways diseases. 2010 Respir. Res. pmid:20540713
Ballard HO et al. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. 2007 Respir. Res. pmid:17550598
Amado-Rodríguez L et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. 2013 Respir. Res. pmid:23663489
Beigelman A et al. Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. 2010 Respir. Res. pmid:20591166
du Toit LC et al. Tuberculosis chemotherapy: current drug delivery approaches. 2006 Respir. Res. pmid:16984627
Komiya K et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. 2017 Respir. Res. pmid:28219384
Legssyer R et al. Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. 2006 Respir. Res. pmid:17064416
Kadota J et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. 2003 Respir Med pmid:12854636
Miravitlles M et al. Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. 2005 Respir Med pmid:15950136
Lode H et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. 2003 Respir Med pmid:14561021
Niederman MS et al. Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. 2006 Respir Med pmid:16531032
Hoeffken G et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. 2001 Respir Med pmid:11453311
Hagberg L et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. 2003 Respir Med pmid:12814146
Kohyama T et al. Clarithromycin inhibits fibroblast migration. 2008 Respir Med pmid:18701271
Abe M et al. A case of diffuse panbronchiolitis effectively treated with low-dose macrolide antibiotics and leukotriene D4/E4 receptor antagonist. 1998 Respir Med pmid:9893782
Kobashi Y et al. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. 2007 Respir Med pmid:16750618
Simoens S et al. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. 2013 Respir Med pmid:23352223
Banerjee D et al. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. 2005 Respir Med pmid:15715188
Carbon C et al. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia. 2006 Respir Med pmid:16376537
Yatera K et al. The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. 2017 Respir Investig pmid:29153420
Higashi F et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza. 2014 Respir Investig pmid:25169846
Suzuki K et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare lung disease from post-marketing surveillance. 2018 Respir Investig pmid:29325687
Heifets LB Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy. 1994 Mar-Apr Res. Microbiol. pmid:7809471
Dautzenberg B Clinical trials in Mycobacterium avium therapy: lessons to take home. 1994 Mar-Apr Res. Microbiol. pmid:7809472
Horgen L et al. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. 1997 Res. Microbiol. pmid:9765852
Yajko DM In vitro activity of antimicrobial agents against the Mycobacterium avium complex inside macrophages from HIV1-infected individuals: the link to clinical response to treatment? 1992 Res. Microbiol. pmid:1455069
Sander P et al. Ribosomal drug resistance in mycobacteria. 1996 Jan-Feb Res. Microbiol. pmid:8761724
Kargar M et al. Real-time PCR for Helicobacter pylori quantification and detection of clarithromycin resistance in gastric tissue from patients with gastrointestinal disorders. 2012 Res. Microbiol. pmid:22177975
Komori T et al. Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats. 1998 Res. Commun. Mol. Pathol. Pharmacol. pmid:9874281
Ives TJ et al. Disposition and functions of clarithromycin in human THP-1 monocytes during stimulated and unstimulated conditions. 2001 Res. Commun. Mol. Pathol. Pharmacol. pmid:12760488
Yatsunami J et al. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. 1997 Res Exp Med (Berl) pmid:9440137
Sharma H et al. Fortuitous vasculitis. 2012 Ren Fail pmid:22250755
Wen YK and Chen ML Crescentic glomerulonephritis associated with non-tuberculous mycobacteria infection. 2008 Ren Fail pmid:18350456
Itatsu T et al. Eradication of Helicobacter pylori in hemodialysis patients. 2007 Ren Fail pmid:17365917
Parola D et al. [Efficacy and safety of clarithromycin in the treatment of community-acquired pneumonia]. 2000 Recenti Prog Med pmid:10705778
Vaira D et al. [Treatment for Helicobacter pylori: current criteria]. 2007 Recenti Prog Med pmid:18044409
Palumbo E et al. [Mycoplasma pneumoniae encephalitis in immunocompetent child]. 2008 Recenti Prog Med pmid:18710062
Zautner AE Adenotonsillar disease. 2012 Recent Pat Inflamm Allergy Drug Discov pmid:22452646
Bergamaschi A et al. Recent Advances in the Treatment of Helicobacter pylori Infection. 2007 Recent Pat Antiinfect Drug Discov pmid:18221177
Campo SM et al. Antibiotic treatment strategies for Helicobacter pylori infection. 2007 Recent Pat Antiinfect Drug Discov pmid:18221161
Leonard S et al. Application of liquid chromatography/ion trap mass spectrometry to the characterization of the related substances of clarithromycin. 2006 Rapid Commun. Mass Spectrom. pmid:16991103
Calza P et al. Identification of the unknown transformation products derived from clarithromycin and carbamazepine using liquid chromatography/high-resolution mass spectrometry. 2012 Rapid Commun. Mass Spectrom. pmid:22730089
Kim HS et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. 2012 Radiology pmid:22371609
Ozdemir A et al. Detection of Helicobacter pylori colonization in dental plaques and tongue scrapings of patients with chronic gastritis. 2001 Quintessence Int pmid:12066673
Lin YH and Liu TC Mycobacterium chelonae infection involving the auricle. 2012 QJM pmid:21908384
Browne G et al. A potential role for keratinocyte growth factor and clarithromycin in the treatment of paraquat overdose. 2010 QJM pmid:20154068
Harvey E and Varatharaj A Round pneumonia. 2014 QJM pmid:23708793
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
Burch LH and Picher M E-NTPDases in human airways: Regulation and relevance for chronic lung diseases. 2006 Purinergic Signal. pmid:18404479
Hasegawa N et al. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. 2009 Pulm Pharmacol Ther pmid:19061965
Yamada K et al. Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. 2014 Pulm Pharmacol Ther pmid:24910464
Morinaga Y et al. Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells. 2009 Pulm Pharmacol Ther pmid:19716898
Gao X et al. Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. 2010 Pulm Pharmacol Ther pmid:19895898
Liu CP et al. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. 2014 Pulm Pharmacol Ther pmid:23518214
Nakamura M et al. Clarithromycin ameliorates pulmonary inflammation induced by short term cigarette smoke exposure in mice. 2015 Pulm Pharmacol Ther pmid:26363279
Martynova AV et al. Emergence of Haemophilus influenzae Strains in the Nasopharynx of Children with Tuberculosis. 2011 Pulm Med pmid:21766017
Rafii R et al. Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease. 2011 Pulm Med pmid:21660228
Figueiredo Bde C and Ibiapina Cda C The role of macrolides in noncystic fibrosis bronchiectasis. 2011 Pulm Med pmid:22292118
Warner A Clarithromycin--a precipitant for acute psychotic stress. 2000 Nov-Dec Psychosomatics pmid:11110120
Mermelstein HT Clarithromycin-induced delirium in a general hospital. 1998 Nov-Dec Psychosomatics pmid:9819955
Jiang F et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. 2015 Psychopharmacology (Berl.) pmid:25510856
Härtig G et al. [Symptomatic psychosis in bland sinus thrombosis and antibiotic therapy]. 1999 Psychiatr Prax pmid:10457975
Mrozińska M [Legionellosis in three children--cases report]. 2005 Przegl Epidemiol pmid:16729426
Mach T and Zahradnik-Bilska J [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. 1999 Prz. Lek. pmid:10575912
Hydzik P et al. [Drug-induced erythrodermia complicated by multiorgan failure--case report]. 2011 Prz. Lek. pmid:22010450
Trzebiatowska I et al. [Psychosis caused by the treatment with clarithromycin--a case report]. 2011 Prz. Lek. pmid:22010468
Zwolińska-Wcisło M and Palka M [Principles of managing Helicobacter pylori infections. Guidelines of the European Society of Gastroenterology in Primary Health Care]. 2000 Prz. Lek. pmid:11293204
Thorley JA et al. Mechanisms of viral entry: sneaking in the front door. 2010 Protoplasma pmid:20446005
Sato Y et al. Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production. 2007 Prostaglandins Leukot. Essent. Fatty Acids pmid:17324565
Miyazaki M et al. Macrolide antibiotics inhibit prostaglandin E2 synthesis and mRNA expression of prostaglandin synthetic enzymes in human leukocytes. 2003 Prostaglandins Leukot. Essent. Fatty Acids pmid:12907132
Björkholm B et al. Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. 2001 Proc. Natl. Acad. Sci. U.S.A. pmid:11717398
Pfister P et al. 23S rRNA base pair 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation 2058A-->G. 2005 Proc. Natl. Acad. Sci. U.S.A. pmid:15795375
Fahey JW et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. 2002 Proc. Natl. Acad. Sci. U.S.A. pmid:12032331
Shmelev EI et al. [Clarythromycin in the treatment of exacerbations of chronic obstructive lung disease]. 2006 Probl Tuberk Bolezn Legk pmid:17002058
James GD et al. Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. 2013 Prim Care Respir J pmid:23839240
Kwan BY and Rabheru K Manic episode associated with clarithromycin in a patient with medically treated depression. 2012 Prim Care Companion CNS Disord pmid:22943025
Sellal A et al. [Maintenance treatment of cerebral toxoplasmosis in AIDS: role of clarithromycin-minocycline combination]. 1996 Presse Med pmid:8685115
Contios S et al. [Mycobacterium marinum tenosynovitis of the abductors]. 2005 Presse Med pmid:15962499
Guillemet C et al. [Clarithromycin-digoxin: an unrecognized interaction in some patients]. 1997 Presse Med pmid:9137381
Couture G et al. [Second case of serum sickness-like reaction to claritrhomycin]. 2016 Presse Med pmid:27542759
Ragnaud JM et al. [Cerebral toxoplasmosis in AIDS. 73 cases. Clinical Epidemiology Group on AIDS in Aquitania]. 1993 Presse Med pmid:8378280
de Masson A et al. Cavitary pulmonary disease in a patient treated with natalizumab. 2014 Presse Med pmid:24742610
Bigard MA [Helicobacter pylori eradication. Therapeutic evolution, value of complementary studies]. 2001 Presse Med pmid:11603094
Mégraud F [Helicobacter pylori: bacteriological aspects, diagnostic methods, and susceptibility to antibiotics]. 2008 Presse Med pmid:18261874
Songné B et al. [Buruli ulcer in Togo: 21 cases]. 2001 Presse Med pmid:11317927
Courillon-Mallet A [Treatment of Helicobacter pylori infection]. 2008 Presse Med pmid:18255253
Morlet-Barla N et al. [Severe hypoglycemia and recurrence caused by disopyramide-clarithromycin interaction]. 2000 Jul 8-15 Presse Med pmid:10938688